<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047680</url>
  </required_header>
  <id_info>
    <org_study_id>201509009RINB</org_study_id>
    <nct_id>NCT04047680</nct_id>
  </id_info>
  <brief_title>eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs</brief_title>
  <official_title>Evolution of Estimated Glomerular Filtration Rate in Chronic Hepatitis C Patients Receiving Sofosbuvir-based or Sofosbuvir-free Direct Acting Antivirals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data regarding the nephrotoxicity of sofosbuvir (SOF) remain controversial. The investigators
      compared the changes of estimated glomerular filtration rate (eGFR) in patients with chronic
      hepatitis C virus (HCV) infection receiving SOF-based or SOF-free direct acting antivirals
      (DAAs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is a major health problem that affects 71 million
      people worldwide. Patients with chronic HCV infection may present with various hepatic and
      extrahepatic manifestations which lead to substantial morbidity and mortality. In contrast,
      the long-term health outcome improves following successful HCV eradication by antiviral
      therapies.

      Owing to the excellent efficacy and safety as well as the short treatment duration, the use
      of interferon (IFN)-free direct acting antivirals (DAAs) has become the standard-of-care for
      managing HCV. Sofosbuvir (SOF) is a pyrimidine nucleotide analogue which acts as the HCV
      ribonucleic acid (RNA) chain terminator by inhibiting HCV non-structural protein 5B (NS5B)
      RNA-dependent RNA polymerase following intrahepatic activation to uridine triphosphate form.
      Dephosphorylation results in the formation of inactive metabolite (GS-331007) that undergoes
      extensive renal excretion. Clinically, SOF is administered once-daily with pangenotypic
      potency, well tolerability and a high genetic barrier to drug resistance. Furthermore, SOF
      can be used in combination with NS3/4A protease inhibitors (PIs), NS5A inhibitors, and/or
      ribavirin (RBV) to achieve high rates of sustained virologic response (SVR). Therefore,
      applying SOF-based DAAs for HCV is welcome to most treating physicians.

      Following the widespread use of SOF-based DAAs for treating HCV in different populations, a
      large-scale real-world HCV-TARGET study enrolling 1,789 patients indicated that patients with
      a baseline eGFR â‰¤ 45 mL/min/1.73m2 were associated with a higher risk of worsening renal
      function than those with a baseline eGFR &gt; 45 mL/min/1.73m2 following SOF-based DAAs.
      Moreover, three retrospective studies showed that SOF-based DAAs negatively affected the
      on-treatment and off-therapy eGFR. On the contrary, other studies showed that the use of
      SOF-based DAAs did not worsen the eGFR. Because most studies were retrospective in nature
      without protocol-defined time point for eGFR assessment or patient election, and did not
      enroll patients receiving SOF-free DAAs as the controls, the investigators thus conducted a
      prospective study to evaluate the evolution of eGFR in patients with chronic HCV infection
      receiving SOF-based or SOF-free DAAs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Slope differences of eGFR</measure>
    <time_frame>Baseline to off-therapy week 24</time_frame>
    <description>Slope differences of eGFR between SOF-based and SOF-free DAAs</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">441</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Renal Disease</condition>
  <condition>Viral Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <description>Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <description>Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir / Velpatasvir Oral Tablet</intervention_name>
    <description>Sofosbuvir/velpatasvir for 12 weeks</description>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir and Ledipasvir</intervention_name>
    <description>Sofosbuvir and ledipasvir for 12 weeks</description>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <other_name>Harvoni</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir Tablets</intervention_name>
    <description>Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks</description>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <other_name>Solvadi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/paritaprevir/ritonavir</intervention_name>
    <description>Ombitasvir/paritaprevir/ritonavir for 12 weeks</description>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <other_name>Viekirax/exviera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir / Grazoprevir Oral Tablet</intervention_name>
    <description>Elbasvir/grazoprevir for 12 weeks</description>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir and Pibrentasvir</intervention_name>
    <description>Glecaprevir/pibrentasvir for 12 weeks</description>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <other_name>Maviret</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C virus-infected patients with compensated liver diseases and baseline
        eGFR of 30 mL/min/1.73m2 or more, who received SOF-based or SOF-free DAAs for 12 weeks, and
        who received off-therapy follow-up until week 24
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV patients receiving SOF-based or SOF-free DAAs for 12 weeks

        Exclusion Criteria:

          -  Decompensated cirrhosis (Child-Pugh B or C)

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2

          -  Active hepatocellular carcinoma (HCC)

          -  Organ transplantation

          -  Hepatitis B virus (HBV) co-infection

          -  Human immunodeficiency virus (HIV) co-infection

          -  Not received off-therapy follow-up till week 24
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Horng Kao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliu</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viral hepatitis C</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Direct acting antiviral agent</keyword>
  <keyword>Sofosbuvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>MK-5172</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

